Picture of Vivimed Labs logo

VIVIMEDLAB — Vivimed Labs Income Statement

0.000.00%
in flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for Vivimed Labs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

2022
March 31st
2023
March 31st
2024
March 31st
2025
March 31st
2026
March 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSPRESS
Standards:
IAS
IAS
IAS
IAS
IAS
Status:FinalFinalFinalFinalPreliminary
Revenue
Total Revenue2,3731,8711,4911,163700
Cost of Revenue
Gross Profit580-1,145619564-37.6
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses2,6364,8241,7421,4952,485
Operating Profit-263-2,953-251-333-1,785
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-648-3,307-458-318-1,763
Provision for Income Taxes
Net Income After Taxes-677-3,285-454-321-1,765
Minority Interest
Net Income Before Extraordinary Items
Net Income-677-3,285-454-321-1,765
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-677-3,285-454-320-1,765
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-8.16-32.6-3.37-3.85-21.1